Arcellx (ACLX) Long-Term Deferred Tax (2021)

Arcellx's (ACLX) quarterly Long-Term Deferred Tax came in at $3.2 million in Q4 2021.

Arcellx (ACLX) Long-Term Deferred Tax (2021) Analysis & Trends

Arcellx's Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $3.2 million for Q4 2021.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $3.2 million in Q4 2021; TTM through Dec 2021 was $3.2 million, a N/A change from a year earlier, with the FY2021 full-year figure at $3.2 million, changed N/A from the prior year.
Long-Term Deferred Tax steadied at $3.2 million in Q4 2021 per ACLX's latest filing.
Across five years, Long-Term Deferred Tax topped out at $3.2 million in Q4 2021 and bottomed at $3.2 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Arcellx	6.48 Bn	6.48 Bn	-

Download Data

Date	Value
Dec 31, 2021	3.17 Mn